Fudan University Shanghai Cancer Center for International Patients
Fudan University Shanghai Cancer Center (FUSCC) is a major specialist cancer hospital in Shanghai with disease-specific surgery, medical oncology, radiation oncology, pathology, imaging, nuclear medicine and multidisciplinary cancer programs. It is particularly relevant for breast, lung/thoracic, prostate, colorectal, pancreatic, liver/biliary and other complex solid tumors.
Quick answer: FUSCC can be an excellent medical fit when the case needs a dedicated oncology center,
but international access should be verified separately from clinical strength. The hospital publishes strong
oncology credentials and current specialist programs; however, it does not currently publish the same clear
government-listed foreign-patient pathway as some Shanghai general hospitals. Confirm the department, campus,
intake route, language support, deposit and expected treatment pathway before booking travel.
✓ Dedicated cancer center
✓ Disease-specific MDT routing
✓ International access verified separately
✓ No guaranteed treatment or outcome
FUSCC at a Glance
FUSCC was founded in 1931 and is affiliated with Fudan University. Its current official materials describe Xuhui and Pudong campuses, close integration with Shanghai Proton and Heavy Ion Center, and a large research and treatment platform focused exclusively on cancer.
Hospital type
Grade-A tertiary specialist cancer hospital under the National Health Commission system.
Main campuses
Xuhui and Pudong, with treatment assignment depending on department and program.
2025 activity
Hospital-reported: about 2.5 million outpatient visits, 80,000 surgeries and 420,000 radiotherapy treatments.
Research platform
National drug-trial institution, precision oncology, cell/gene therapy and multiple disease-focused research programs.
Activity figures above are institution-reported service volumes, useful for understanding scale but not evidence that a particular patient will achieve a specific outcome.
When FUSCC Is a Strong Hospital to Consider
A solid tumor needs disease-specific staging and treatment planning
FUSCC is organized around specialist oncology departments and MDT teams rather than general medicine. That is useful when pathology, staging, surgery, radiation and systemic therapy need to be coordinated.
Surgery vs radiation vs systemic treatment is unclear
A specialist center can help when the main value of travel is not a single procedure but a multidisciplinary decision about sequencing, operability, recurrence or organ preservation.
A precision or later-line oncology question exists
Examples include molecularly selected systemic treatment, clinical-trial review, PSMA-based prostate treatment or a complex recurrence requiring disease-specific oncology expertise.
FUSCC is not automatically the best destination for every cancer patient. Hematologic malignancies
and CAR-T may route more naturally to a center such as Ruijin; brain-tumor or complex neurologic cases may need a
dedicated neuro center; and urgent unstable patients need immediate local care rather than an international referral.
Major Cancer Programs at FUSCC
| Cancer area | Why FUSCC may be relevant | Questions an international patient should ask |
|---|---|---|
| Breast cancer | Dedicated breast cancer center with surgery, radiotherapy, medical oncology and precision-research programs. | Subtype, stage, neoadjuvant strategy, breast conservation, reconstruction, radiation and systemic-treatment sequencing. |
| Lung & thoracic cancer | Thoracic MDT integrating surgery, radiation oncology, medical oncology, pathology, imaging, nuclear medicine and supportive care. | Operability, molecular testing, targeted/immunotherapy options, chemoradiation, oligometastatic or recurrence strategy. |
| Prostate & GU cancers | Urologic oncology surgery plus pathology, radiation, hormone/systemic therapy and nuclear medicine; Lu-177-PSMA pathway reported in 2026. | Risk group, surgery vs radiation, PSMA imaging, mCRPC sequencing and whether radioligand therapy is appropriate. |
| Colorectal cancer | Large colorectal surgical program and multidisciplinary research, including organ-preservation strategies in selected rectal-cancer research. | Resectability, rectal organ preservation, liver/lung metastases, neoadjuvant therapy and need for combined surgery. |
| Pancreatic cancer | Dedicated pancreatic surgery and research platform; current 2026 Fudan work includes AI-assisted surgical planning. | Resectability, vascular involvement, neoadjuvant treatment, surgical approach and whether pathology needs re-review. |
| Liver & biliary tumors | Hepatobiliary surgery plus interventional and multidisciplinary options for primary and metastatic liver tumors. | Resectability, local treatment, systemic therapy, colorectal liver metastases and whether another liver/transplant center is more appropriate. |
| Gynecologic cancer | Gynecology within a dedicated oncology center, supported by pathology, medical oncology and radiation oncology. | Surgical stage, fertility/organ preservation when relevant, chemotherapy, radiation and recurrence strategy. |
| Head & neck / bone / soft tissue / other solid tumors | Disease-specific surgical departments backed by specialist pathology, radiation and systemic oncology. | Whether the case needs a dedicated rare-tumor MDT, complex reconstruction, pathology review or another national specialty center. |
Breast Cancer at FUSCC
FUSCC has a long-established Shanghai Breast Cancer Medical Center and a disease-specific breast program combining surgery with radiation and systemic treatment. Current 2026 Fudan reporting also shows active work in precision neoadjuvant therapy for HR+/HER2-negative breast cancer and difficult metastatic subgroups such as triple-negative breast cancer with brain metastases.
Typical reasons to request review
- Early breast cancer: breast conservation vs mastectomy
- Need for neoadjuvant systemic therapy
- HER2-positive or triple-negative treatment sequencing
- Complex recurrence or metastatic disease
- Second pathology / molecular review
What not to infer from research headlines
- A published FUSCC trial is not automatically standard care
- A trial result does not mean the protocol is open now
- Foreign-patient eligibility cannot be assumed
- Subgroup results are not guarantees for an individual patient
- The exact drug combination must be confirmed against current practice
Related: Breast Cancer Treatment in China.
Lung and Thoracic Cancer at FUSCC
FUSCC’s thoracic cancer MDT combines thoracic surgery, radiation oncology, medical oncology, pathology, radiology, nuclear medicine, interventional radiology and supportive disciplines. This structure is useful when the main question is not simply “where can I get chemotherapy?” but whether the patient should have surgery, chemoradiation, molecularly targeted treatment, immunotherapy or a recurrence-focused strategy.
Surgery-first review
- Stage and nodal assessment
- Resection extent
- Molecular/pathology review
- Need for perioperative systemic therapy
Combined treatment
- Radiation planning
- Concurrent or sequential systemic therapy
- Resectability after induction treatment
- Organ and lung-function limits
Precision systemic treatment
- Driver-mutation review
- PD-L1 and pathology
- Targeted / immune therapy
- Local treatment for selected metastases
Related: Lung Cancer Treatment in China.
Prostate Cancer and Lu-177-PSMA at FUSCC
Current 2026 development: Fudan University Shanghai Medical College reported that FUSCC introduced
Lu-177-PSMA radioligand therapy for selected advanced prostate-cancer patients. The report describes PSMA imaging,
multidisciplinary evaluation and use in patients whose disease has progressed after previous treatment.
This makes FUSCC particularly interesting for a PSMA-positive advanced prostate-cancer question, but the correct referral still begins with treatment history, current testosterone, metastatic pattern, PSMA PET/CT, marrow/kidney function and previous androgen-receptor or chemotherapy exposure.
Do not travel because a hospital owns the technology. A patient with localized prostate cancer may
need surveillance, surgery or radiation rather than radioligand therapy. Lu-177-PSMA is a later-line, selected
treatment question—not a general “prostate cancer cure.”
Related: Prostate Cancer Treatment in China.
Radiation Oncology, Proton Therapy and Heavy-Ion Treatment
FUSCC operates a large radiation-oncology platform and is closely integrated with Shanghai Proton and Heavy Ion Center. The practical question for an international patient is not whether particle therapy exists in Shanghai—it does—but whether it provides a meaningful advantage for the tumor, location, prior radiation history and surrounding organs compared with modern photon radiotherapy.
Modern external-beam treatment
Used across many tumor types and often combined with surgery or systemic treatment according to disease stage.
Proton / heavy ion
Consider when dose distribution or radiobiological factors may materially improve the treatment plan—not simply because the technology is newer.
Previous radiation matters
Send the old radiation plan and dose summary. Prior fields and organ-at-risk dose can determine whether another course is feasible.
Related: Proton Therapy in China.
Pathology and Molecular Review Before Treatment
For many international referrals, the highest-value first step is not a new procedure but confirming what the tumor actually is. FUSCC’s pathology platform includes disease-specific pathology, immunohistochemistry and molecular pathology; its English institutional materials describe high-volume consultation work and integration with MDT care.
Send when available
- Original pathology report
- Glass slides or digital pathology
- Paraffin blocks if requested
- Immunohistochemistry results
- Molecular / genomic results
- Operation pathology and margin/nodal report
Why a pathology re-review can change the route
- Tumor subtype can change drug selection
- Grade and biomarkers can change risk
- Rare tumors can be misclassified
- Old testing may be incomplete for current options
- Trial eligibility often depends on exact pathology/molecular criteria
Clinical Trials at FUSCC: Strong Research Does Not Equal Automatic Eligibility
FUSCC is a National Drug Clinical Trial Institution and describes a large active research portfolio. Its 2024 institutional overview reported 588 newly initiated clinical trials, with most led by FUSCC. That signals research depth, but it does not mean a patient can book a trial as a treatment package.
Protocol
The exact trial ID, phase, drug, disease subtype and recruitment status must be identified.
Eligibility
Stage, biomarkers, prior drugs, measurable disease, organ function and washout periods can determine eligibility.
International access
A Chinese trial may recruit without accepting overseas self-referred patients. Confirm nationality/residency and follow-up requirements directly.
International Patient Access: What Is Confirmed and What Still Needs Verification
| Access point | What we can verify | What still needs confirmation |
|---|---|---|
| Foreign-patient program | FUSCC’s English site documents a historical International and VIP patient program linked to an MSH agreement. | Current 2026 intake office, eligibility, language support and direct overseas self-pay process. |
| Shanghai international medical-tourism pilot | The Shanghai Government’s published 2024 list of 13 public international-medical pilot hospitals did not include FUSCC. | Whether FUSCC has since added a separate government-recognized international route or new service channel. |
| Insurance / direct pay | Historical FUSCC material documents an MSH payment-network agreement. | Current insurer roster, authorization rules, deposits and whether the specific treatment is covered. |
| Remote review | Some disease-specific FUSCC materials describe international consultation and multidisciplinary review. | Whether a formal overseas second-opinion service is currently bookable for this diagnosis. |
| Clinical trial | FUSCC has major clinical-research activity. | Foreign-patient eligibility for the exact protocol and whether repeated follow-up in China is required. |
Parkmega’s rule: medical strength and international accessibility are two separate checks. We can
recommend FUSCC medically while still advising you not to buy flights until the relevant department confirms that it
can review and accept the case.
FUSCC Xuhui and Pudong Campuses
No. 270 Dong’an Road, Shanghai
Official FUSCC contact information lists the Xuhui campus at 270 Dong’an Road, postal code 200032, with hospital switchboard 021-6417-5590.
No. 4333 Kangxin Highway, Shanghai
Official FUSCC contact information lists the Pudong campus at 4333 Kangxin Highway, postal code 201321, using the same hospital switchboard 021-6417-5590.
Do not choose a hotel until the appointment states the campus. Departments and treatment programs
can be distributed across campuses, and a consultation, procedure and admission may not all occur in the same place.
Appointments, Remote Review and What to Confirm Before Travel
Identify the exact department
Breast surgery, thoracic surgery, urology, hepatobiliary surgery, pancreatic surgery, radiation oncology and medical oncology are different routes.
Send records first
Pathology, imaging and previous treatment should be reviewed before a foreign patient assumes travel is worthwhile.
Ask for the likely pathway
Clarify additional tests, outpatient vs admission, procedure or drug plan, approximate stay and whether a final decision requires in-person review.
Confirm practical access
Campus, language support, registration method, deposit/payment, estimated dates and the contact handling the international case.
FUSCC Treatment Costs for International Patients
FUSCC does not publish a universal international cancer-treatment price list that can be safely applied to
every case. Any quote should follow review of diagnosis, stage, intended treatment and expected length of stay.
Diagnostic costs
Pathology review, molecular testing, MRI/CT/PET, endoscopy and repeat biopsy can materially change the final plan.
Treatment costs
Surgery, radiation, chemotherapy, targeted therapy, immunotherapy, nuclear medicine and particle therapy have different cost structures.
International-service costs
Interpreter, coordination, deposits, international ward options and insurance administration may add separate charges if available.
Ask for a written estimate listing what is included, what is excluded, which costs are only provisional and what happens if staging changes the treatment plan after arrival.
Related: Cancer Treatment Cost in China.
FUSCC vs Other Major Shanghai Hospitals
| Hospital | Typical reason to consider it | How it differs from FUSCC |
|---|---|---|
| FUSCC | Dedicated solid-tumor oncology, cancer surgery, radiation, medical oncology, pathology, nuclear medicine and cancer research. | Most cancer-specific of this comparison; international access is less clearly published than some general hospitals. |
| Ruijin Hospital | Hematology, selected CAR-T pathways, endocrinology/metabolic disease and complex general tertiary care. | Better fit for many hematologic malignancy/CAR-T questions; broader general-hospital platform. |
| Zhongshan Hospital | Cardiovascular disease, liver cancer, renal and pulmonary disease within a major general academic hospital. | Useful when cancer overlaps with complex non-oncology organ disease or a strong liver/general tertiary program is needed. |
| Huashan Hospital | Neurology, neurosurgery, brain tumors, infection, dermatology and complex neurologic disease. | Often more natural for primary neuro-oncology/neurosurgical routing and neurologic complexity. |
| Fuda Cancer Hospital | International cancer-hospital route with selected interventional/local treatment programs. | International access is more explicitly marketed; FUSCC is the larger public academic cancer platform. |
What Medical Records Should You Send for a FUSCC Review?
Minimum useful cancer file
- Diagnosis and cancer type
- Pathology report and biomarker results
- Recent CT / MRI / PET reports
- DICOM imaging files when available
- Current stage and sites of disease
- Operation summaries
- Radiotherapy summary / plan if previously treated
For advanced or recurrent disease
- Complete systemic-treatment history with dates
- Response / progression after each line
- Molecular and germline testing if relevant
- Recent blood count, liver and kidney function
- Current symptoms and performance status
- Pathology slides / blocks if re-review may be needed
- Your exact question for the Chinese team
Send the Cancer Records Before Booking Shanghai
We’ll check whether FUSCC is medically appropriate for the diagnosis, compare it with other China centers where needed, and confirm whether there is a realistic international route before you plan travel.
✓ Hospital fit checked by cancer type
✓ International route confirmed before travel
✓ No obligation to book
Frequently Asked Questions
Direct answers to the main questions international patients ask about FUSCC before planning cancer treatment in Shanghai.
Is Fudan University Shanghai Cancer Center a good hospital for cancer treatment?
FUSCC is a dedicated tertiary cancer hospital affiliated with Fudan University and managed within China’s National Health Commission system. It is especially relevant when the case needs disease-specific oncology surgery, radiation oncology, medical oncology, pathology, nuclear medicine or a multidisciplinary cancer review. The best fit still depends on the exact cancer type, stage and treatment question.
Can international patients go to Fudan University Shanghai Cancer Center?
Foreign patients may be treated at major Chinese public hospitals, but FUSCC does not currently publish a clear, comprehensive English intake pathway equivalent to some Shanghai hospitals’ government-listed international departments. Its English site documents a historical International and VIP patient program, but current overseas self-pay access, language support, deposits and appointment steps should be reconfirmed before travel.
What cancers does FUSCC treat?
FUSCC has disease-specific services across breast cancer, thoracic and lung cancer, colorectal and other gastrointestinal cancers, pancreatic cancer, liver and biliary tumors, prostate and other genitourinary cancers, gynecologic cancers, head and neck tumors, bone and soft-tissue tumors, brain and spine tumors, and other solid tumors. The hospital also provides medical oncology, radiation oncology, pathology, imaging, nuclear medicine and supportive cancer care.
Is FUSCC strong for breast cancer?
Yes. FUSCC has a dedicated breast cancer center and multidisciplinary breast program covering surgery, radiotherapy and systemic treatment. Current 2026 Fudan reporting also shows active breast-cancer research in precision neoadjuvant treatment and difficult subgroups. A specific patient still needs subtype, stage and prior-treatment review before a treatment plan is chosen.
Does FUSCC treat lung cancer?
Yes. FUSCC has a thoracic cancer multidisciplinary team involving thoracic surgery, radiation oncology, medical oncology, pathology, imaging, nuclear medicine and other specialties. For an international patient, the key question is whether the case needs surgery, chemoradiation, systemic treatment, molecularly targeted therapy or a second opinion on recurrence.
Does FUSCC offer Lu-177-PSMA therapy for prostate cancer?
In February 2026, Fudan University Shanghai Medical College reported the clinical rollout of Lu-177-PSMA radioligand therapy at FUSCC for selected patients with advanced PSMA-positive prostate cancer, including metastatic castration-resistant disease after prior treatment. Eligibility requires specialist assessment and PSMA imaging; the existence of the program does not mean every overseas patient can receive it.
Does FUSCC provide proton or heavy-ion therapy?
FUSCC is closely integrated with Shanghai Proton and Heavy Ion Center. Particle therapy should be evaluated as a radiation question rather than assumed to be superior to surgery or modern photon radiotherapy. The relevant team should explain why proton or heavy-ion treatment is expected to improve the risk-benefit balance for the specific tumor.
Can an international patient join a clinical trial at FUSCC?
FUSCC is a major clinical-research center and reports a large trial portfolio, but trial activity is not the same as foreign-patient eligibility. Each protocol has its own diagnosis, biomarker, previous-treatment, organ-function and residency or follow-up requirements. International eligibility must be confirmed with the study team before travel.
How much does treatment at FUSCC cost for international patients?
There is no reliable universal international tariff published for FUSCC. Costs depend on pathology review, imaging, surgery, radiotherapy, systemic drugs, nuclear medicine, hospitalization and whether treatment is self-pay or covered through an accepted arrangement. Request a written case-specific estimate after the relevant department has reviewed the records.
What records should I send before asking FUSCC for a review?
Send the diagnosis, pathology report, pathology slides or digital pathology when available, recent imaging reports and DICOM files, stage, treatment history, operation and radiation summaries, current medication list, recent blood tests and relevant molecular or genetic results. Add one clear question such as surgery, radiation, recurrence, trial eligibility or PSMA treatment.
Sources and Verification
- Fudan University Shanghai Cancer Center — official hospital website and current contact information. Current Xuhui/Pudong campus addresses, hospital switchboard and appointment entry points. FUSCC official website.
- FUSCC — official English institutional overview (2024). Hospital history, NHC/Fudan affiliation, Xuhui and Pudong campuses, integration with Shanghai Proton and Heavy Ion Center, clinical departments, medical-service scale and clinical-research platform. FUSCC English overview.
- FUSCC — 2026 official hospital introduction / recruitment brief. Current 2025 year-end scale: two campuses, 2,177 open beds, 50 clinical/medical-technology departments and national clinical platforms. FUSCC 2026 hospital profile.
- Fudan University Shanghai Medical College — June 27, 2026. Current institutional update reporting 2025 service volumes of approximately 2.5 million outpatient visits, 80,000 surgeries and 420,000 radiotherapy treatments; used here as hospital-reported scale, not outcome evidence. FUSCC 2026 institutional update.
- FUSCC — Clinical Departments. Official directory showing colorectal surgery, brain/spine surgery, radiation oncology, pancreas surgery, breast surgery, gynecology, urology surgery, head/neck surgery, hepatobiliary surgery, thoracic surgery, interventional radiology, medical oncology and other oncology departments. FUSCC Clinical Departments.
- FUSCC — Breast Cancer MDT / Breast Surgery. Disease-specific breast program and multidisciplinary treatment across surgery, radiation and systemic therapy. FUSCC Breast Cancer MDT.
- Fudan University Shanghai Medical College — August 21, 2026. Current breast-cancer research report on precision neoadjuvant treatment for HR+/HER2-negative disease; cited as research activity, not as proof of standard treatment or foreign-patient eligibility. FUSCC 2026 breast-cancer research.
- FUSCC — Thoracic Cancer MDT. Multidisciplinary structure involving thoracic surgery, radiation oncology, medical oncology, pathology, radiology, nuclear medicine and other specialties. FUSCC Thoracic Cancer MDT.
- FUSCC — Urology Surgery. Official department scope includes prostate, bladder, kidney and other genitourinary cancers with surgery and multimodal oncology. FUSCC Urology Surgery.
- Fudan University Shanghai Medical College — February 5, 2026. Clinical rollout of Lu-177-PSMA radioligand therapy at FUSCC for selected advanced prostate-cancer patients after assessment, including PSMA imaging and multidisciplinary evaluation. FUSCC Lu-177-PSMA 2026.
- FUSCC — Hepatobiliary Surgery. Official department material on primary and secondary liver tumors, cholangiocarcinoma, multidisciplinary surgery and interventional options. FUSCC Hepatobiliary Surgery.
- FUSCC — Diagnostic Radiology / Pathology. Official descriptions of tumor imaging, nuclear medicine, disease-specific pathology, immunohistochemistry and molecular pathology. FUSCC Diagnostic Radiology and FUSCC Pathology.
- Shanghai Municipal Government — international medical-tourism pilot, September 23, 2024. The published first cohort lists 13 public hospitals; FUSCC is not on that list. This is used only to explain why a current foreign-patient route should be confirmed rather than assumed. Shanghai international medical pilot list.
- FUSCC — historical International and VIP patient program / MSH agreement. Evidence that FUSCC previously launched an International and VIP patient program and payment-network cooperation. This page is treated as historical evidence only; current insurer and intake arrangements must be reconfirmed. FUSCC International/VIP program notice.
Evidence rule: recent 2026 hospital/Fudan sources are used for current institutional developments. Older English departmental pages are used for department scope and program structure, not for current staffing, volume, prices or guaranteed availability. International-access claims are kept separate from medical-strength claims.
Last evidence check: September 2026. Appointment routes, language support, insurer contracts, trial recruitment, specialist schedules, treatment availability and prices can change; reconfirm before travel.
Check the Department, Treatment Question and International Route First
Send pathology, imaging, stage and treatment history. We’ll determine whether FUSCC is a strong match, what department should review the case and what still needs confirmation before travel.